title: Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.
abstract: OBJECTIVE
  The present phase I study was planned to define the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of the combination of paclitaxel and cisplatin in patients with advanced or recurrent gastric cancer, and to recommend a dose for the phase II study.
  
  
  METHODS
  Patients were required to have performance status of 0 to 1, to be between 15 and 74 years of age, and to have adequate organ function. The cisplatin was administered at a fixed dose of 25mg/m2 and paclitaxel was administered at four dose levels (60, 70, 80, and 90mg/m2). Plasma sampling was performed to characterize the pharmacokinetics and pharacodynamics of paclitaxel.
  
  
  RESULTS
  All of the 15 patients entered were assessable for toxicity and response and were subject to analysis of dose-limiting toxicity (DLT) and MTD. Neutropenia (grade 4, for 3 days or more; n=2) indicated DLT at dose level 4 (90mg/m2). The MTD for this regimen was 90mg/m2/week of paclitaxel for 3 weeks. Tumor response occurred in 7 of the 15 patients and the overall response rate was 57.1%. The pharmacokinetic profiles of paclitaxel were similar to those observed after the administration of each dose as a single agent.
  
  
  CONCLUSIONS
  Our study demonstrated that the level 3 dosage (80mg/m2 of paclitaxel and 25mg/m2 of cisplatin) is recommended for this combination chemotherapy. This phase I study showed favorable antitumor activity and fewer adverse reactions relative to other types of chemotherapy.
authors.affiliation: Department of Surgery 1, University of Occupational and Environmental Health, Japan. n-nagata@med.uoeh-u.ac.jp
authors.forename: Naoki
authors.initials: N
authors.lastname: Nagata
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kojima
authors.forename: Ken
authors.initials: K
authors.lastname: Kondo
authors.forename: Naoki
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: Takanori
authors.initials: T
authors.lastname: Matsui
authors.forename: Masato
authors.initials: M
authors.lastname: Kataoka
authors.forename: Wataru
authors.initials: W
authors.lastname: Takiyama
authors.forename: Yumi
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nakazato
authors.forename: Kyoujiro
authors.initials: K
authors.lastname: Araki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Itoh
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakamoto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002945:Cisplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use; D010166:Palliative Care / Q000379:methods*; D018579:Patient Selection; D011379:Prognosis; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D002945:Cisplatin